<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Drugs</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Innovent submits NDA for CLDN18.2 ADC for gastric cancer</title>
      <description>
        <![CDATA[Innovent Biologics Co. Ltd.’s Claudin18.2-targeted antibody-drug conjugate (ADC), arcotatug tavatecan (IBI-343, TAK-921), met the primary endpoint in the international multicenter phase III G-Hope-001 trial in advanced gastric cancer, according to interim results.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731830</guid>
      <pubDate>Tue, 09 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731830-innovent-submits-nda-for-cldn182-adc-for-gastric-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Gastric-cancer-illustration.webp?t=1610744617" type="image/png" medium="image" fileSize="551352">
        <media:title type="plain">Gastric cancer</media:title>
      </media:content>
    </item>
    <item>
      <title>ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins </title>
      <description>
        <![CDATA[If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s biotechnology sector, it was that the industry’s center of gravity is shifting. While Chinese companies once relied heavily on PD-1 antibodies and licensing deals to gain international visibility, this year’s oral presentations showcased a broader innovation base.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731829</guid>
      <pubDate>Tue, 09 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731829-asco-2026-chinese-biopharma-arrives-at-asco-with-pivotal-wins</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/China-compass.webp?t=1770672078" type="image/jpeg" medium="image" fileSize="512881">
        <media:title type="plain">China compass </media:title>
      </media:content>
    </item>
    <item>
      <title>‘Disciplined’ $665M deal moves Oscotec’s cevidoplenib to Agios  </title>
      <description>
        <![CDATA[Agios Pharmaceuticals Inc.’s potential $665 million deal for Oscotec Inc.’s cevidoplenib, a phase III-ready oral SYK inhibitor to treat immune thrombocytopenia, marks a new chapter of development focused on cancer therapy resistance for Oscotec, CEO Yoon Tae-young said.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731828</guid>
      <pubDate>Tue, 09 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731828-disciplined-665m-deal-moves-oscotecs-cevidoplenib-to-agios</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deal-handshake-with-coin-chart-background.webp?t=1704408549" type="image/jpeg" medium="image" fileSize="317806">
        <media:title type="plain">Deal handshake with coin, chart background</media:title>
      </media:content>
    </item>
    <item>
      <title>NMPA gives conditional nods to drugs by Lupeng, Vcare, Staidson</title>
      <description>
        <![CDATA[China’s National Medical Products Administration (NMPA) on June 4 granted conditional approvals to two oncology drugs from Lupeng Pharmaceutical Co. Ltd. and Vcare Pharmatech Co. Ltd., as well as one hemophilia drug developed by Staidson Biopharmaceutical Co. Ltd.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731712</guid>
      <pubDate>Tue, 09 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731712-nmpa-gives-conditional-nods-to-drugs-by-lupeng-vcare-staidson</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/Wood-approved-stamp-red.webp?t=1670969940" type="image/png" medium="image" fileSize="323015">
        <media:title type="plain">Red wooden approved stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>Japan backs Oncolys virus therapy for esophageal cancer</title>
      <description>
        <![CDATA[Japan has granted marketing approval to Oncolys Biopharma Inc.’s oncolytic adenovirus product, Telomelysin (suratadenoturev, OBP-301), for treating esophageal cancer in patients who are not eligible for curative resection or chemoradiotherapy. The approval marks the first oncolytic adenovirus product approved for esophageal cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731711</guid>
      <pubDate>Tue, 09 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731711-japan-backs-oncolys-virus-therapy-for-esophageal-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/esophageal-cancer-illustration.webp?t=1741727451" type="image/jpeg" medium="image" fileSize="514154">
        <media:title type="plain">Illustration of cancer on the esophagus</media:title>
      </media:content>
    </item>
    <item>
      <title>Wuxi Apptec insists it’s ‘not a Chinese military company’ </title>
      <description>
        <![CDATA[Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military company,” which makes it a “biotechnology company of concern” under the Biosecure Act. “Such designation is mistaken and baseless,” the global contract research, development and manufacturing organization said in an open letter to its life sciences partners. “We will pursue every available avenue to correct this mistake.” That includes appealing the designation.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731710</guid>
      <pubDate>Tue, 09 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731710-wuxi-apptec-insists-its-not-a-chinese-military-company</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Wuxi-Apptec-signage.webp?t=1781036355" type="image/jpeg" medium="image" fileSize="104349">
        <media:title type="plain">Wuxi Apptec signage </media:title>
        <media:description type="plain">Credit: Wuxi Apptec</media:description>
      </media:content>
    </item>
    <item>
      <title>Columbia researchers use base editing to modify human embryo genome</title>
      <description>
        <![CDATA[Scientists at Columbia University have used base editing to make precise changes in the genomes of human embryos, avoiding the damage to chromosomes that occurs following two-stranded DNA cuts with conventional Crispr-Cas9 editing.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731708</guid>
      <pubDate>Tue, 09 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731708-columbia-researchers-use-base-editing-to-modify-human-embryo-genome</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/DNA-gene-edit-genomics.webp?t=1747837759" type="image/jpeg" medium="image" fileSize="1061729">
        <media:title type="plain">DNA double helix under a magnifying glass</media:title>
      </media:content>
    </item>
    <item>
      <title>GLP-1s and more weigh in at ADA</title>
      <description>
        <![CDATA[GLP-1 receptor agonists remained center stage at the 2026 Scientific Sessions of the American Diabetes Association with Boehringer Ingelheim GmbH and Astrazeneca plc, joining the leaders, Eli Lilly and Co. and Novo Nordisk A/S, in presenting data for their respective GLP-1 drugs.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731706</guid>
      <pubDate>Tue, 09 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731706-glp-1s-and-more-weigh-in-at-ada</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Obesity/Close-up-of-injector-pen-in-hands.webp?t=1736374814" type="image/jpeg" medium="image" fileSize="117912">
        <media:title type="plain">Close-up of injector pen in hands</media:title>
      </media:content>
    </item>
    <item>
      <title>Pheon Therapeutics discovers new CDCP1-targeting ADCs</title>
      <description>
        <![CDATA[Pheon Therapeutics Ltd. has patented antibody-drug conjugates, comprising an antibody targeting CDCP1 covalently linked to a cytotoxic drug through a linker, that are potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731772</guid>
      <pubDate>Tue, 09 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731772-pheon-therapeutics-discovers-new-cdcp1-targeting-adcs</link>
    </item>
    <item>
      <title>City Therapeutics advances RNAi pipeline with series B financing</title>
      <description>
        <![CDATA[City Therapeutics Inc. has completed a $99.5 million series B financing to support its pipeline of RNA interference (RNAi) therapeutics and accelerate its next-generation RNAi engineering platform.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731762</guid>
      <pubDate>Tue, 09 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731762-city-therapeutics-advances-rnai-pipeline-with-series-b-financing</link>
    </item>
    <item>
      <title>Moderna’s mRNA-4194 cleared for clinic for Lynch syndrome</title>
      <description>
        <![CDATA[The University of Oxford and Moderna Inc. have announced authorization by the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a phase I/II study of mRNA-4194, Moderna’s investigational mRNA-based cancer vaccine for Lynch syndrome. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/731760</guid>
      <pubDate>Tue, 09 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731760-modernas-mrna-4194-cleared-for-clinic-for-lynch-syndrome</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Mrna-therapeutic-illustration.webp?t=1778251655" type="image/png" medium="image" fileSize="958605">
        <media:title type="plain">Illustration of messenger RNA</media:title>
      </media:content>
    </item>
    <item>
      <title>CNTY-813 enables durable glucose control without immunosuppression need</title>
      <description>
        <![CDATA[At the recent American Diabetes Association meeting, researchers from Century Therapeutics Inc. presented preclinical efficacy data on CNTY-813, an induced pluripotent stem cell (iPSC)-derived cell therapy engineered using the company’s proprietary Allo-Evasion 5.0 platform.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731758</guid>
      <pubDate>Tue, 09 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731758-cnty-813-enables-durable-glucose-control-without-immunosuppression-need</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Diabetes-pancreas-islets.webp?t=1681310705" type="image/png" medium="image" fileSize="713568">
        <media:title type="plain">Illustration of pancreas, close up of islet</media:title>
      </media:content>
    </item>
    <item>
      <title>China deals highlight biopharma evolution, reports LEK</title>
      <description>
        <![CDATA[In 2025, China’s outbound life sciences and biopharma deals reached nearly $100 billion, about 12 times the level seen in 2021, underscoring how quickly global appetite for Chinese assets has accelerated, according to a recent report by L.E.K. Consulting. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/731530</guid>
      <pubDate>Tue, 09 Jun 2026 08:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731530-china-deals-highlight-biopharma-evolution-reports-lek</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/China-deals-illustration.webp?t=1780424261" type="image/jpeg" medium="image" fileSize="130740">
        <media:title type="plain">China map/flag with silhouettes of business people</media:title>
      </media:content>
    </item>
    <item>
      <title>Clinical footwork pays off in Tango’s PDAC combo phase I/II</title>
      <description>
        <![CDATA[Tango Therapeutics Inc. will be sitting down with the U.S. FDA soon to discuss pivotal work ahead based on what Cantor analyst Eric Schmidt called “amazing” data from the phase I/II study of vopimetostat, a PRMT5 inhibitor, paired with Revolution Medicines Inc.’s RAS(ON) inhibitors in patients with MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC) as well as non-small cell lung cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731691</guid>
      <pubDate>Mon, 08 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731691-clinical-footwork-pays-off-in-tangos-pdac-combo-phase-i-ii</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Pancreatic-cancer-anatomy.webp?t=1780952171" type="image/jpeg" medium="image" fileSize="160961">
        <media:title type="plain">Pancreatic cancer anatomy</media:title>
      </media:content>
    </item>
    <item>
      <title>Nurix signs 4th and largest partnership to develop BTK degrader</title>
      <description>
        <![CDATA[Building on its partnerships with Gilead Sciences Inc., Sanofi SA and Pfizer Inc., Nurix Therapeutics Inc. brought on Roche Holding AG to help develop bexobrutideg, an oral degrader of Bruton’s tyrosine kinase (BTK).&nbsp;“I really can’t think of a better partner to maximize the opportunity for bexobrutideg to a wide range of patients,” Jason Kantor, Nurix’s chief business officer, told investors on a conference call, later pointing out that Roche has multiple drugs targeting B cells.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731690</guid>
      <pubDate>Mon, 08 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731690-nurix-signs-4th-and-largest-partnership-to-develop-btk-degrader</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deal-partnership-chain-link.webp?t=1588276656" type="image/png" medium="image" fileSize="220515">
        <media:title type="plain">Gold chain link engraved with "partnership"</media:title>
      </media:content>
    </item>
    <item>
      <title> Incyte nabs potential VWD game-changer in Vega deal; J&amp;J buys Firefly</title>
      <description>
        <![CDATA[In its largest acquisition to date, Incyte Inc. snagged rights to phase III-stage VGA-039, a monoclonal antibody the firm said could offer a new standard of care in von Willebrand disease (VWD), in a buyout of Vega Therapeutics Inc. that includes a $1.25 billion up-front payment and up to $750 million tied to the achievement of sales milestones. The announcement was followed shortly by news of another buyout, Johnson & Johnson’s deal to acquire Firefly Bio Inc. for $1 billion in cash, both moves continuing this year’s trend of larger, more strategic M&A transactions.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731689</guid>
      <pubDate>Mon, 08 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731689-incyte-nabs-potential-vwd-game-changer-in-vega-deal-j-and-j-buys-firefly</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Collage-of-businesspeople.webp?t=1736806854" type="image/jpeg" medium="image" fileSize="308749">
        <media:title type="plain">Collage of businesspeople</media:title>
      </media:content>
    </item>
    <item>
      <title>LBL-051: Broad immune targeting in autoimmune disease </title>
      <description>
        <![CDATA[Researchers at Obleno Bio Inc. have reported preclinical efficacy data for LBL-051-S3, a trispecific T-cell engager antibody targeting CD3, CD19 and BCMA, in nonhuman primate models.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731743</guid>
      <pubDate>Mon, 08 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731743-lbl-051-broad-immune-targeting-in-autoimmune-disease</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Antibodies-research-discovery-immune.webp?t=1772641847" type="image/jpeg" medium="image" fileSize="240482">
        <media:title type="plain">Illustration of magnifying glass and antibodies</media:title>
      </media:content>
    </item>
    <item>
      <title>Skape Bio unlocks GPCR targets with de novo-designed miniproteins</title>
      <description>
        <![CDATA[Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The scientific community has explored small molecules, antibodies and nanobodies to develop ligands. Skape Bio Inc. is betting on creating miniproteins, a strategy that brings precise solutions for different functions.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731737</guid>
      <pubDate>Mon, 08 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731737-skape-bio-unlocks-gpcr-targets-with-de-novo-designed-miniproteins</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/Beta2-Adrenergic-receptor-GPCR-protein-molecule.webp?t=1780929969" type="image/jpeg" medium="image" fileSize="676137">
        <media:title type="plain">3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.</media:title>
        <media:description type="plain">β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.</media:description>
      </media:content>
    </item>
    <item>
      <title>ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins </title>
      <description>
        <![CDATA[If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s biotechnology sector, it was that the industry’s center of gravity is shifting. While Chinese companies once relied heavily on PD-1 antibodies and licensing deals to gain international visibility, this year’s oral presentations showcased a broader innovation base.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731634</guid>
      <pubDate>Fri, 05 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731634-asco-2026-chinese-biopharma-arrives-at-asco-with-pivotal-wins</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/China-compass.webp?t=1770672078" type="image/jpeg" medium="image" fileSize="512881">
        <media:title type="plain">China compass </media:title>
      </media:content>
    </item>
    <item>
      <title>‘Disciplined’ $665M deal moves Oscotec’s cevidoplenib to Agios  </title>
      <description>
        <![CDATA[Agios Pharmaceuticals Inc.’s potential $665 million deal for Oscotec Inc.’s cevidoplenib, a phase III-ready oral SYK inhibitor to treat immune thrombocytopenia, marks a new chapter of development focused on cancer therapy resistance for Oscotec, CEO Yoon Tae-young said.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731632</guid>
      <pubDate>Fri, 05 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731632-disciplined-665m-deal-moves-oscotecs-cevidoplenib-to-agios</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deal-handshake-with-coin-chart-background.webp?t=1704408549" type="image/jpeg" medium="image" fileSize="317806">
        <media:title type="plain">Deal handshake with coin, chart background</media:title>
      </media:content>
    </item>
    <item>
      <title>AxS007 penetrates BBB for breast cancer brain metastases</title>
      <description>
        <![CDATA[About 90% of brain metastases are often limited therapeutically speaking due to the impermeable blood-brain barrier (BBB). Nanocarry Therapeutics Ltd. has presented AxS007, a novel insulin-mediated nanocarrier that delivers multiple copies of trastuzumab and pertuzumab across the BBB, using native insulin as a brain transporter and increasing brain exposure.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731675</guid>
      <pubDate>Fri, 05 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731675-axs007-penetrates-bbb-for-breast-cancer-brain-metastases</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Blood-Brain-Barrier-Illustration.webp?t=1678203491" type="image/png" medium="image" fileSize="856287">
        <media:title type="plain">Illustration of brain in head highlighting the blood-brain barier.</media:title>
      </media:content>
    </item>
    <item>
      <title>Pfizer’s integrin β6 ADC advances intravesical therapy for NMIBC</title>
      <description>
        <![CDATA[Researchers from Pfizer reported preclinical efficacy of PF-08052667, an antibody-drug conjugate (ADC) targeting integrin β6 (ITGB6), in non-muscle-invasive bladder cancer (NMIBC) models.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731672</guid>
      <pubDate>Fri, 05 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731672-pfizers-integrin-6-adc-advances-intravesical-therapy-for-nmibc</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/ADC-antibody-drug-conjugate-green.webp?t=1706306980" type="image/jpeg" medium="image" fileSize="182154">
        <media:title type="plain">3D rendering of drug linked to antibody</media:title>
      </media:content>
    </item>
    <item>
      <title>Ona raises $86.6M series B for ADCs to treat advanced cancers</title>
      <description>
        <![CDATA[Antibody-drug conjugate (ADC) specialist Ona Therapeutics SL has closed an oversubscribed series B at $86.6 million, as clinical development of the lead program ONA-255 in advanced treatment-resistant breast cancer gathers steam.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731620</guid>
      <pubDate>Thu, 04 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731620-ona-raises-866m-series-b-for-adcs-to-treat-advanced-cancers</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/3D-dollar-sign.webp?t=1624487200" type="image/png" medium="image" fileSize="316216">
        <media:title type="plain">3D dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>SCOTUS breathes new life into skinny labels</title>
      <description>
        <![CDATA[The U.S. Supreme Court handed Hikma Pharmaceuticals and the entire generic industry a big victory June 4 with its 9-0 opinion ensuring the future of skinny labels and correcting the Federal Circuit’s flawed understanding of infringed inducement.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731619</guid>
      <pubDate>Thu, 04 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731619-scotus-breathes-new-life-into-skinny-labels</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Generic-drugs.webp?t=1588352361" type="image/png" medium="image" fileSize="183798">
        <media:title type="plain">Generic drugs and bottle</media:title>
      </media:content>
    </item>
    <item>
      <title>Autobahn on the fast track with bipolar thyroid agonist</title>
      <description>
        <![CDATA[Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous system thyroid hormone receptor agonist, or thyromimetic, is moving toward a registrational path and a clinical readout in major depressive disorder.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731618</guid>
      <pubDate>Thu, 04 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731618-autobahn-on-the-fast-track-with-bipolar-thyroid-agonist</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Depression-and-medication.webp?t=1720465598" type="image/jpeg" medium="image" fileSize="70638">
        <media:title type="plain">Woman taking medication for mental illness</media:title>
      </media:content>
    </item>
    <item>
      <title>Innovent submits NDA for CLDN18.2 ADC for gastric cancer</title>
      <description>
        <![CDATA[Innovent Biologics Co. Ltd.’s Claudin18.2-targeted antibody-drug conjugate (ADC), arcotatug tavatecan (IBI-343, TAK-921), met the primary endpoint in the international multicenter phase III G-Hope-001 trial in advanced gastric cancer, according to interim results.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731617</guid>
      <pubDate>Thu, 04 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731617-innovent-submits-nda-for-cldn182-adc-for-gastric-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Gastric-cancer-illustration.webp?t=1610744617" type="image/png" medium="image" fileSize="551352">
        <media:title type="plain">Gastric cancer</media:title>
      </media:content>
    </item>
    <item>
      <title>Zynlonta Lotis position in DLBCL strains ADC shares</title>
      <description>
        <![CDATA[ADC Therapeutics SA blamed patients’ advanced age on the death imbalance in the phase III Lotis-5 confirmatory trial testing Zynlonta (loncastuximab tesirine-lpyl) in combination with rituximab to treat relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Whatever the reason, Wall Street wasn’t pleased and shares (NYSE:ADCT) closed June 4 at $1.32, down 57%, or $1.77.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731616</guid>
      <pubDate>Thu, 04 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731616-zynlonta-lotis-position-in-dlbcl-strains-adc-shares</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Diffuse-large-B-cell-lymphoma---isometric-view.webp?t=1780608328" type="image/jpeg" medium="image" fileSize="141240">
        <media:title type="plain">Diffuse large B-cell lymphoma - isometric view</media:title>
      </media:content>
    </item>
    <item>
      <title>Idefine announces Kleefstra syndrome gene therapy collaboration</title>
      <description>
        <![CDATA[Idefine, The Kleefstra Syndrome Foundation, has established a collaboration with UT Southwestern Medical Center to advance development of a potential gene therapy to treat Kleefstra syndrome, a rare neurodevelopmental disorder caused by changes or loss of the <em>EHMT1</em> gene, which plays a critical role in brain development and function.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731656</guid>
      <pubDate>Thu, 04 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731656-idefine-announces-kleefstra-syndrome-gene-therapy-collaboration</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Gene-therapy-research-pic.webp?t=1588872515" type="image/png" medium="image" fileSize="467422">
        <media:title type="plain">DNA illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>CEPI backs Pop Biotechnologies’ nanoparticle vaccine platform</title>
      <description>
        <![CDATA[The Coalition for Epidemic Preparedness Innovations (CEPI) will provide up to $9.7 million in additional funding to Pop Biotechnologies Inc. to advance the company’s Pop Bio SNAP (Spontaneous Nanoliposome Antigen Particle) protein vaccine platform into a phase I trial.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731654</guid>
      <pubDate>Thu, 04 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731654-cepi-backs-pop-biotechnologies-nanoparticle-vaccine-platform</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Nanoparticle-illustration.webp?t=1735833924" type="image/jpeg" medium="image" fileSize="311893">
        <media:title type="plain">Nanoparticle illustration </media:title>
      </media:content>
    </item>
    <item>
      <title>Sotio Biotech’s SOT-106 designated orphan drug for osteosarcoma</title>
      <description>
        <![CDATA[Sotio Biotech AS’s SOT-106 has been granted orphan drug designation by the FDA for the treatment of osteosarcoma. SOT-106 is a next-generation antibody-drug conjugate targeting leucine-rich repeat-containing 15 (LRRC15), a clinically validated target broadly expressed across sarcoma subtypes and in tumor-associated stroma.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731653</guid>
      <pubDate>Thu, 04 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731653-sotio-biotechs-sot-106-designated-orphan-drug-for-osteosarcoma</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/osteosarcoma-bone-cancer-knee-illustration.webp?t=1780586547" type="image/jpeg" medium="image" fileSize="560760">
        <media:title type="plain">Illustration of bone cancer in the knee</media:title>
      </media:content>
    </item>
  </channel>
</rss>
